天演药业上涨5.03%，报2.09美元/股，总市值9845.90万美元

Core Insights - Tianyan Pharmaceuticals (ADAG) experienced a 5.03% increase in stock price, reaching $2.09 per share, with a total market capitalization of $98.45 million as of July 30 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be $103,200, reflecting a significant year-over-year decrease of 99.43% [1] - The net profit attributable to the parent company is expected to be -$33.42 million, a decline of 76.41% compared to the previous year [1] Company Overview - Tianyan Pharmaceuticals is a biopharmaceutical company focused on the development of clinical products driven by its proprietary platform, specializing in novel cancer immunotherapies based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to develop new antibodies with high safety and efficacy, aiming to benefit more cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating potentially innovative or best-in-class products globally [1]